NCT03886311: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
- State
- Under way
- Phase
- Phase 2
- People
- 200 planned
- Started
- 15 May 2019
- Primary completion
- 31 Dec 2030
- Arms
- Talimogene laherparepvec, Nivolumab and Trabectedin
- Results
- None posted
- 22 Mar 2019: Trial registered
- 15 May 2019: Trial started